07.03.2013 09:20 Uhr, Quelle: Wallstreet online
AmVac´s Vaccine Against RSV Attains Next Milestone
ZUG, Switzerland, March 7, 2013 /PRNewswire/ AmVac AG announces new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate …
Weiterlesen bei Wallstreet online
JustMac.info